臨床婦人科産科76巻8号

2022年08月発行

今月の臨床 HPVワクチン勧奨再開―いま知りたいことのすべて HPVワクチンの有効性

9価ワクチンの有効性と安全性―海外の知見から

著者： 宮城悦子¹ 吉岡俊輝¹ 魚本真理¹ 道佛美帆子¹ 今井雄一¹

所属機関： ¹横浜市立大学医学部産婦人科学教室

ページ範囲：P.762 - P.768

●本邦においても2021年2月より9価HPVワクチンが任意接種として接種可能となったが，適用は9歳以上の女性のみである．

●世界では，9価HPVワクチンに関する有効性・安全性のエビデンスが蓄積し，若年者への2回接種や男性への定期接種が進んでおり，2価・4価からの移行に関するデータも公表されている．

●日本では2022年4月より2価・4価HPVワクチンの定期接種は正常化に向かい，25歳までの無料キャッチアップ接種も開始されるが，9価ワクチンの海外の知見の周知は遅れている．

参考文献

1）de Martel C, et al : Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 141 : 664-670, 2017

2）Forman D, et al : Global burden of human papillomavirus and related diseases. Vaccine 30（suppl 5） : F12-F23, 2012

9添付文書．2021年2月改定https://pins.japic.or.jp/pdf/newPINS/00068902.pdf

4）Huh WK, et al : Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16―26 years : a randomized, double-blind trial. Lancet 390 : 2143-2159, 2017

5）Riethmuller D, et al : Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. BMC Public Health 15 : 453, 2015

添付文書．2020年12月改訂　https://pins.japic.or.jp/pdf/newPINS/00059715.pdf

7）WHO : Immunization stress-related responses : a manual for program managers and health professionals to prevent, identify and respond to stress-related responses following immunization. 20 December, 2011https://www.who.int/publications/i/item/978-92-4-151594-8

8）Human papillomavirus vaccines : WHO position paper, May 2017. Nkly Epidemiol Rec 92 : 241-268, 2017

9）Iversen OE, et al : Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA 316 : 2411-2421, 2016

10）Olsson SE, et al : Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age : interim analysis after 8 years of follow-up. Papillomavirus Res 10 : 100203, 2020

11）Donken R, et al : Immunogenicity of 2 and 3 doses of the quadrivalent human papillomavirus vaccine up to 120 months postvaccination : follow-up of a randomized clinical trial. Clin Infect Dis 71 : 1022-1029, 2020

12）Donken R, et al : Non-inferior antibody levels for HPV16/18 afterextended two-dose schedules compared with a six-month interval : findings of a systematicreview and meta-analysis. Hum Vaccin Immunother 17 : 3554-3561, 2021

13）WHO : Vaccination schedule for human papilloma virus.　https://immunizationdata.who.int/pages/schedule-by-disease/hpv.html?ISO_3_CODE=&TARGETPOP_GENERAL=BOTH

14）Australian Government Department of Health : National Immunisation Program Schedule 1 July 2020　https://www.health.gov.au/sites/default/files/documents/2020/09/national-immunisation-program-schedule-for-all-people.pdf

15）NSW Health : HPV vaccination for boys to commence in NSW. 22 November, 2012.　https://www.health.nsw.gov.au/news/Pages/20121122_02.aspx

16）CDC : Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV　https://www.cdc.gov/hpv/downloads/9vhpv-guidance.pdf

17）Statens Serum Institut : Childhood vaccination programme. updated 20 August, 2019.　https://en.ssi.dk/vaccination/the-danish-childhood-vaccination-programme

18）Office fèdèral de la santè publique : Plan de vaccination suisse 2020　https://www.infovac.ch/docs/public/-main/plan-de-vaccination-suisse-2020.pdf

19）厚生労働省：第66回厚生科学審議会予防接種・ワクチン分科会副反応検討部会資料．令和3年8月4日，2021　https://www.mhlw.go.jp/stf/shingi2/0000208910_00028.html

20）Garland S, et al : Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Vaccine 33 : 6855-6864, 2015

21）World Health Organization（WHO） : Human papillomavirus vaccines : WHO position paper, May 2017- Recommendations. Vaccine 35 : 5753-5755, 2017

22）Meites E, et al : Use of a 2-dose schedule for human papillomavirus vaccination-Updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal wkly Rep 65 : 1405-1408, 2016